Obalon Enters Into Commercial Lease for its First Company-Owned Retail Weight Loss Center
July 23 2019 - 8:30AM
Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated
medical technology company with the first and only FDA-approved
swallowable, gas-filled intragastric balloon system for the
treatment of obesity, announces that it has entered into a
commercial lease for its first Company-owned weight loss center. As
part of a strategy to increase patient access and utilization of
its novel gastric balloon weight loss system, Obalon intends to own
and operate a network of retail centers throughout the United
States that focus solely on patients wishing to lose weight using
the Obalon Balloon System. The first Obalon retail center will be
located in San Diego and the Company is targeting this fall for its
grand opening.
“We are transitioning the business with the intent to create a
network of Obalon retail centers in the United States, where
patients can access our novel weight loss treatment in an
environment dedicated to a standardized experience and achieve the
most successful outcomes,” said Bob MacDonald, Obalon’s Chief
Retail Officer. “We have shown in the past that patient interest in
the Obalon Balloon System has been high with moderate
direct-to-consumer marketing, and we believe Obalon-owned centers
may provide a more efficient means to convert patient interest into
Obalon customers. We are targeting the opening of our first center
in San Diego this fall.”
About Obalon Therapeutics, Inc. Obalon
Therapeutics, Inc. (NASDAQ:OBLN) is a San Diego-based company
focused on developing and commercializing novel technologies for
weight loss. For more information, please
visit www.obalon.com.
Forward-Looking StatementsTo the extent that
statements contained in this press release are not descriptions of
historical facts regarding Obalon Therapeutics, they are
forward-looking statements reflecting the current beliefs and
expectations of management made pursuant to the safe harbor of the
Private Securities Reform Act of 1995. Such forward-looking
statements involve substantial risks and uncertainties that could
cause Obalon Therapeutics' future results, performance or
achievements to differ significantly from those expressed or
implied by the forward-looking statements. Obalon Therapeutics
undertakes no obligation to update or revise any forward-looking
statements. For a description of the risks and uncertainties that
could cause actual results to differ from those expressed in these
forward-looking statements, as well as risks relating to Obalon
Therapeutics' business in general, please refer to Obalon
Therapeutics’ annual report on Form 10-K filed with the Securities
and Exchange Commission on February 22, 2019, its quarterly report
on Form 10-Q filed with the Securities and Exchange Commission on
May 10, 2019, and its future periodic reports filed with the
Securities and Exchange Commission.
For Obalon Therapeutics, Inc.
Investor Contact: William Plovanic President & Chief
Financial Officer Obalon Therapeutics, Inc. Office: +1 760 607 5103
wplovanic@obalon.com
Obalon Therapeutics (NASDAQ:OBLN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Obalon Therapeutics (NASDAQ:OBLN)
Historical Stock Chart
From Apr 2023 to Apr 2024